


## LSZ-102

**Cat. No.:** HY-111486  
**CAS No.:** 2135600-76-7  
**Molecular Formula:** C<sub>25</sub>H<sub>17</sub>F<sub>3</sub>O<sub>4</sub>S  
**Molecular Weight:** 470.46  
**Target:** Estrogen Receptor/ERR  
**Pathway:** Vitamin D Related/Nuclear Receptor  
**Storage:** -20°C, stored under nitrogen  
 \* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (212.56 mM; Need ultrasonic) H <sub>2</sub> O : < 0.1 mg/mL (insoluble)				
	Preparing Stock Solutions	<b>Solvent</b>	<b>Mass</b>	<b>1 mg</b>	<b>5 mg</b>
		<b>Concentration</b>			
		<b>1 mM</b>			
		<b>5 mM</b>			
In Vivo	Preparing Stock Solutions	<b>10 mM</b>			
			2.1256 mL	10.6279 mL	21.2558 mL
			0.4251 mL	2.1256 mL	4.2512 mL
			0.2126 mL	1.0628 mL	2.1256 mL
	Please refer to the solubility information to select the appropriate solvent.				
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1.67 mg/mL (3.55 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 1.67 mg/mL (3.55 mM); Clear solution				
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 1.67 mg/mL (3.55 mM); Clear solution				

### BIOLOGICAL ACTIVITY

<b>Description</b>	LSZ-102 is a potent, orally bioavailable selective estrogen receptor degrader with an IC <sub>50</sub> of 0.2 nM.
<b>IC<sub>50</sub> &amp; Target</b>	estrogen receptor <sup>[1]</sup>
<b>In Vitro</b>	LSZ-102 is a potent, orally bioavailable selective estrogen receptor degrader with an IC <sub>50</sub> of 0.2 nM and currently in Phase I/Ib trials for the treatment of ERα positive breast cancer. LSZ-102 induces significant degradation of ERα after 24 h, when given as a 10 μM solution to MCF-7 cells. Robust inhibition of cell proliferation in MCF-7 cells is observed upon incubation with LSZ-102 with a half inhibitory concentration of 1.7 nM. Results demonstrate that LSZ-102 effectively inhibits the

estrogen-induced activation of the ERE-luciferase reporter using charcoal-stripped serum treated with E2 with IC<sub>50</sub> of 0.3 nM [1].  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

Treatment of the mice with LSZ-102 once daily at 20 mg/kg results in significant tumor growth inhibition as compare to the control group treated with vehicle alone, resulting in tumor stasis (mean change in tumor volume of LSZ-102 vs control=%Δ T/ΔC of 2.4% on day 48, p<0.05). Dosing of 3 mg/kg solution of LSZ-102 in male Sprague-Dawley rats results in 33% bioavailability and a dose-normalized exposure of 620 nM·h<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## PROTOCOL

#### Kinase Assay <sup>[1]</sup>

Growth factors depleted MCF-7 ERE-luc cells are used and seeded (10 000 cells/well) in 96-well plates in CSS medium. After overnight incubation, cells are treated with LSZ-102 in the presence of estradiol (0.1 nM) for 24 h. Cells are then lysed and quantified for luciferase activity using Bright-Glo assay<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### Animal Administration <sup>[1]</sup>

Female athymic nude mice are used for tumor xenograft studies. MCF-7 cells are subcutaneously injected (200 μL/animal) in the right axillary mammary fat pad area. Tumor volume and body weights are measured twice weekly. When tumors reach an average volume of ~200 mm<sup>3</sup>, mice are randomized into different groups. Animals are orally administered vehicle alone or 20 mg/kg LSZ-102 daily or 60 mg/kg tamoxifen 5 days per week<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- Harvard University. 2023 Mar. 30487357.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Tria GS, et al. Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degradar (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer. J Med Chem. 2018 Apr 12;61(7):2837-2864.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA